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Background: Dying tumor cells after irradiation could promote the proliferation of living tumor cells might cause
tumor relapse and treatment failure. Our previous study showed that activated caspase-3 after irradiation probably
participates in tumor repopulation. In this study, we investigated whether high mobility group box 1(HMGB1) is also
involved in tumor repopulation.
Methods: Colorectal tumor cells were irradiated. The cleaved caspase-3 (CC3) in irradiated tumor cells and HMGB1
in the supernatant of irradiated tumor cells were detected by Western blot. A large number of irradiated colorectal
tumor cells (feeder cells) were then co-cultured with a small number of luciferase-labeled living colorectal tumor
cells (reporter cells) and proliferation of reporter cells was measured by bioluminescence imaging. The CC3 and
HMGB1 protein expression in colorectal tumor and peritumoral tissues were detected by immunohistochemistry
and their correlation with prognosis were analyzed.
Results: The irradiated colorectal tumor cells underwent apoptosis and necrosis and produced CC3 in tumor cells
and HMGB1 in the supernatant of cultured cells. The increased expression of secretory HMGB1 correlated with CC3
level and proliferating cell nuclear antigen (PCNA) after irradiation in vitro. The irradiated dying cells remarkably
stimulated living tumor cell proliferation. Interestedly, immunohistochemistry staining showed that positive HMGB1,
CC3, and Ki67 expression were significantly higher in colorectal tumor tissues than in peritumoral tissues (p <0.01).
The Kaplan-Meier survival analysis revealed that high HMGB1, CC3, and Ki67 levels were significantly associated with
poor prognosis (p <0.05, p <0.01). Multivariate analysis using Cox proportional hazards model showed that TNM staging
and HMGB1 were independent prognostic factors in patients with colorectal cancer (CRC) (p <0.01, p <0.001).
Conclusion: Both apoptotic and necrotic cells could stimulate proliferation of living tumor cells, and the increased
expression of CC3 and HMGB1 in tumor cells could be new markers for poor prognosis in colorectal cancer patients.
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Resistance to chemotherapy and radiotherapy is a univer-
sal obstacle in cancer treatment and one of the main
causes of tumor relapse and treatment failure. However,
the mechanisms responsible for drug or radiation resist-
ance have yet to be fully elucidated [1]. A recent study of
ours demonstrated that dying tumor cells after radiother-
apy can stimulate the proliferation of residual living tumor
cells, which may be a possible mechanism of tumor resist-
ance and repopulation after radiotherapy [2]. This process
was found to be associated with the activation of caspase-
3 and caspase-7. The activated caspases can further acti-
vate downstream effectors. One of these key effectors is
cytosolic calcium-independent phospholipase A2 (iPLA2),
which can promote prostaglandin E2 (PGE2) production.
PGE2 can then stimulate the proliferation of living tumor
cells in vitro and in vivo [2, 3]. A recent study by Kurtova
et al. also demonstrated that chemotherapy effectively
induces apoptosis and PGE2 release, which paradoxically
promotes neighboring cancer stem cell repopulation and
leads to subsequent chemoresistance [4]. Ford et al. also
demonstrated that apoptotic tumor cells promoted tumor
growth, angiogenesis, and accumulation of tumor associ-
ated macrophages in aggressive B cell lymphomas [5].
However, tumor resistance and progression after therapy
is a highly complex process and many signaling pathways
may be involved, and whether cell death signaling path-
ways other than apoptosis could promote tumor progres-
sion has not been clarified.
High mobility group box 1 (HMGB1) is a highly con-
served nuclear protein. In cell nuclei, HMGB1 functions
as a DNA chaperone to regulate DNA replication, recom-
bination, transcription, and repair [6]. Also, HMGB1 can
be released or secreted from cells into the extracellular
matrix to function as a signaling molecule. In general,
HMGB1 is passively released from dead, dying, or injured
cells. Therefore, extracellular HMGB1 is thought to be an
optimal “necrosis marker” selected by the innate immune
system to recognize tissue damage [7]. The extracellular
HMGB1 binds to several cell surface receptors, including
the receptor for advanced glycation end products (RAGE)
[8]. RAGE was the first receptor demonstrated to bind
HMGB1 [9], and the binding of HMGB1 to RAGE stimu-
lates proliferation and differentiation of cancer cells as
well as tissue regeneration [10]. Recent studies showed
that HMGB1 could promote chemotherapy resistance in
colorectal cancer and lung adenocarcinoma through
HMGB1 mediated autophagy [11, 12]. In the clinic, the
expression of RAGE is closely associated with invasion
and metastasis of gastric cancer [13] and colorectal cancer
[14]. Hongo et al. also found that HMGB1 expression
detected by immunohistochemistry correlates with the
resistance of preoperative chemoradiotherapy in lower
rectal cancer [15].In this study, the role of HMGB1 in CRC tumor cell
proliferation induced by irradiated dying cells was inves-
tigated in vitro, and the clinical significance of HMGB1
expression in colorectal cancer patients was analyzed by
comparing its expression with the expression of CC3,
RAGE, and Ki67.
Materials and methods
Cell culture and irradiation
HT29, HCT8, SW620, CaCO2, RKO cells were purchased
from the Chinese Academy of Science (Shanghai, China)
and cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) (Thermo Scientific Inc., Beijing, China) contain-
ing 10 % fetal bovine serum (FBS) (Tianhang Biological
Technology Co., Ltd., Hangzhou, China), supplemented
with 1 % penicillin and 1 % streptomycin at 37 °C under
5 % CO2. Cells were irradiated with X-rays using an Oncor
linear accelerator (Siemens, Amberg, Germany). The dose
rate was approximately 3.6 Gy/min.
Tumor cell proliferation model in vitro
HT29 cells irradiated with various doses of X-rays were
seeded into 24-well plates at a density of 2.5 × 105/well.
After the cells became attached (about 6 h), the reporter
cells (non-irradiated HT29 with firefly luciferase and
GFP fusion gene, Fluc), were seeded into the plates at a
density of 1000/well and co-cultured for about 2 weeks.
The substrate D-luciferin (Promega, Madison, WI, USA)
prepared for a final concentration of 0.15 mg/ml was
added, and the luciferase activity was detected with
NC100 instrument (Berthold Technologies, Bad Wildbad,
Germany). The final luciferase signal readouts were ana-
lyzed quantitatively by the manufacturer supplied software
and represented the status of accelerated proliferation of
reporter cells.
Western blot
Total protein was extracted with RIPA lysis buffer con-
taining protease inhibitor cocktail (Roche). Western blot
was performed as previously described [16]. The mem-
branes were incubated with primary antibodies purchased
from Cell Signaling Technology (MA, USA. HMGB1,
1:1000 dilution; PCNA, 1:1000 dilution; CC3, 1:1000
dilution; β-actin, 1:1000 dilution) overnight at 4 °C and
then incubated with secondary antibodies (1:5000 dilution,
Jackson Immuno Research, PA, USA) for 2 h at room
temperature. ECL Plus (Roche, Basel, Switzerland) was
used to visualize the signals on the membrane.
To detect secretory HMGB1, cell culture supernatants
were collected at 0 h, 6 h, 12 h, 1 day, 2 day, 3 day,
4 day, and 5 day. Secretory HMGB1 was detected
through Western blotting shown above. Gray value of
the bands in the Western blot was analyzed using
ImageJ software [17].
Table 1 Summary of clinical characteristics in 73 patients of
colon cancer
Characteristics Patient no. (%)
Sex Male 39(53.42)
Female 34(46.58)
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Exponentially growing HT29 cells were seeded into 6-cm
dishes and irradiated. Cells were trypsinized and sus-
pended 48 h after irradiation. The suspended cells were
stained with Annexin V and propidium iodide (PI) using
FITC Annexin V Apoptosis Detection Kit (BD company,
USA) and subjected to flow cytometry using Accuri C6
Flow Cytometer (BD company). AnnexinV+ PI− cells were
regarded as apoptotic cells, while AnnexinV+ PI+ cells as
necrotic cells [18, 19].
Patient selection
A total of 73 patients that underwent radical resection for
CRC between January 1, 2009 and December 30, 2010 at
First People’s Hospital, Shanghai Jiao Tong University
were included in this study. The number of patients meets
the requirement of the estimated size for two-sample com-
parison of survivor functions (Log-rank test, Freedman
method, α = 0.05, power = 0.80). CRC was diagnosed by
morphological features and immunohistochemical stain-
ing. Information about lymph node and distant metastasis
and disease-related death were obtained from medical
records or telephone interview. 28 peritumoral tissues
were collected from the 73 CRC patients during the same
time period. All procedures were done ethically with pre-
approval from the Ethics Committee for Human Studies,
Shanghai Jiao Tong University.
Among the 73 patients, 39 were male and 34 were
female with a mean age of 70 years and a range of 37 to
93 years. Staging was performed according to the TNM
system recommended by the American Joint Committee
on Cancer [20]. Five cases were stage I, 34 were stage II,
30 were stage III, and 4 were stage IV. Lymph node metas-
tasis was found in 36 cases, and distant metastasis was
found in 4 cases. 27 patients died during the follow-up.
The average follow-up period was 41.137 months with a
maximum of 71 months and a median of 48 months. Clin-
ical information about the 73 CRC samples is described in
detail in Table 1.
Tissue microarrays
Tissue microarrays (TMAs) were created from formalin-
fixed and paraffin-embedded tissue blocks at the Depart-
ment of Pathology, First People’s Hospital, Shanghai Jiao
Tong University. The slides of 73 patients were reviewed
by an experienced pathologist and the representative area
of each tumor was marked on the slide. All cases were
adenocarcinoma with different degrees of differentiation.
Immunohistochemistry staining and scoring
The tissue slides were deparaffinized, and antigen retrieval
was performed by immersing the slides into boiling
EDTA-Tris buffer (pH 8.2) for 4 min. After incubation
with 3 % H2O2 for 15 min, slides were incubated withprimary antibody overnight (4 °C), followed by Gtvision III
detection system (Gene Tech, Shanghai, China) as second-
ary antibody for 30 min at room temperature. DAB (3,3-di-
aminobenzidine) was used to visualize positive immune
reaction. Nuclei were counterstained with hematoxylin.
The primary antibodies included CC3 (Cell Signaling
Technology, 1:300 dilution), HMGB1 (Cell Signaling Tech-
nology, 1:400 dilution), RAGE (Abcam, 1:100 dilution),
and Ki67 (Epitomics, 1:1000 dilution) antibody.
HMGB1 and RAGE immunoreactivity was scored and
put into 3 categories based on staining extent and intensity
according to a previously described protocol [14, 21]: nega-
tive expression was assigned when almost all cells showed
no immunoreactivity or uncertain weak staining, low ex-
pression was assigned when less than 25 % of tumor cells
showed weak to moderate immunoreactivity, high expres-
sion was assigned when more than 25 % of tumor cells
showed moderate to intense immunoreactivity. CC3 was
scored and put into 3 categories based on staining extent
(negative for no staining or uncertain staining, ≤10 % posi-
tive staining for low expression, >10 % positive staining for
high expression) [3]. Ki67 index was assessed by estimation
of the percentage of positive tumor cells (low expression
for 0 % to 40 % positive staining, high expression for 41 %
to 100 % positive staining) [22, 23]. The representative
images are provided in Additional file 1: Figure S1.
Statistical analysis
Categorical variables were assessed using the χ2 test and
Fisher exact test. The correlation between HMGB1 and
CC3, RAGE, or Ki67 was examined using Spearman’s
rank method. The cumulative survival time was obtained
Fig. 1 (See legend on next page.)
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Fig. 1 HMGB1 stimulated cell proliferation after irradiation. (a) The irradiated HT29 cells (feeder cells) significantly stimulated HT29 Fluc labeled
cells growth compared to non-irradiated HT29 feeder cells or reporter alone cells (No feeder). **p <0.01. (b) Cell death detection by flow cytometry.
(c) Western blot of correlated expressions of HMGB1 and PCNA protein in colon cancer cells. Relative intensity changes of HMGB1 and PCNA were
analyzed through gray value using software ImageJ. Positive correlation between HMGB1 expression and proliferative marker was observed in colon
cell lines. (d) Western blot of HMGB1, PCNA, and caspases-3 levels in HT29 and HCT8 cells. Cells were irradiated at 10 Gy. The supernatant HMGB1 was
elevated significantly in both cell lines, while there was no obvious change of intracellular HMGB1. PCNA and increased caspases-3 cleavage were also
observed after irradiation
Table 2 Comparison of HMGB1, CC3 and Ki67 expressions in
colorectal cancer with peritumor tissues
Tumor tissue (n) Peritumor tissue (n) p value
HMGB1 Negative 12 20 0.000*
low 29 8
high 32 0
CC3 Negative 18 26 0.000*
low 35 2
high 20 0
Ki67 low 38 24 0.003*
high 35 4
*,statistically significant
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log-rank test. Cox proportional hazards model was used
for multivariate analysis. All probabilities were 2-tailed. A
p <0.05 was considered statistically significant. All statis-
tical analyses were performed using Stata 12.0 software for
Windows (StataCorp, Texas, USA).
Results
Dying cells stimulate tumor cell proliferation
The co-cultured cell model [3] was used to investigate the
role of dying cells in tumor cell proliferation. Unlabeled
HT29 cells (feeder) were irradiated at various doses (0, 2,
6, 10, and 14 Gy) and then co-cultured with Fluc labeled
living HT29 cells (reporter). Bioluminescence signals re-
leased by reporter cells were used to gauge the extent of
proliferation of living tumor cells. As shown in Fig. 1a, all
irradiated feeders, especially those that were irradiated
with a dose higher than 6Gy, could stimulate living tumor
cell proliferation, which was characterized by a significant
increase in luciferase activity of reporter cells. This obser-
vation suggests that, after irradiation, dying cells can
stimulate tumor cell growth. Although apoptotic cells can
promote tumor growth and proliferation of surviving cells
after tumor irradiation [3], this study showed that the
percentage of apoptosis in cell death modalities was not
very high. In contrast, necrotic cells were also observed
(Fig. 1b).
Secretory HMGB1 coupled with increased CC3 after
irradiation in vitro
Extracellular HMGB1 is thought to be an optimal “necro-
sis marker” [24, 25] and PCNA is a well-known prolifera-
tive marker [26]. Western blot showed that the signal
intensities of the two proteins were higher or lower in
colon cancer cell lines (Fig. 1c), indicating the positive cor-
relation of HMGB1 with a proliferative marker.
To explore the role of HMGB1 in tumor cell prolifera-
tion, HT29 and HCT8 cells in exponential growth phase
were irradiated for 10Gy, and secretory HMGB1 in cell
culture supernatant and intracellular HMGB1 in cell lysate
was detected simultaneously by Western blot. We ob-
served that secretory HMGB1 increased at 6 h after radio-
therapy. Expression of the proliferative marker PCNA was
also found to increase rapidly after radiotherapy. CC3 was
significantly increased (Fig. 1d). These findings suggestthat the increase in HMGB1 release was accompanied by
an increase in CC3 protein level.
The clinical significance of HMGB1, CC3, RAGE, and Ki67
in colorectal cancer patients
HMGB1, RAGE, CC3 and Ki67 proteins were detected by
immunohistochemistry. CC3 positive staining was mainly
localized in the cytoplasm and some at the membrane,
while HMGB1, RAGE and Ki67 were localized in the nu-
cleus (Additional file 1: Figure S1). Positive HMGB1, CC3,
and Ki67 expression was significantly higher in tumor
tissues than in peritumoral tissues (p <0.01, Table 2). The
high CC3 levels positively correlated with high TNM
staging and distant metastasis (Table 3). Positive RAGE
expression correlated with higher TNM staging and
lymph node metastasis. Ki67 expression was found be as-
sociated with lymph node metastasis. In contrast, HMGB1
was unexpectedly found to be associated with neither
TNM staging nor metastasis.
The Kaplan-Meier survival analysis revealed that TNM
staging was clearly correlated with overall survival in
CRC (Fig. 2a). Interestedly, high HMGB1 expression was
significantly associated with poor prognosis. In addition,
positive CC3 and Ki67 expression was also significantly
correlated with shorter survival time in CRC patients
(p = 0.0281, p = 0.0006, p = 0.033, respectively; Fig. 2b, c, d,
Table 4). Multivariate analysis using Cox proportional
hazards model showed that TNM staging and HMGB1
(p = 0.000 and p = 0.008, respectively), but not CC3 and
Ki67 (p = 0.998 and p = 0.347, respectively) were inde-
pendent prognostic factors in CRC patients (Table 4).
Table 3 Correlation of clinicopathologic parameters with HMGB1, CC3, Ki6 and RAGE expressions
HMGB1 + (%) p CC3 + (%) p Ki67 + (%) p RAGE+(%) p
Sex 0.964 0.081 0.121 0.524
Male 17(43.59) 14(35.90) 22(56.41) 26(66.67)
female 15(44.12) 6(17.65) 13(38.24) 25(73.53)
Age 0.684 0.138 0.769 0.589
≤70 y 14(46.67) 11(36.67) 15(50) 22(73.33)
>70 y 18(41.86) 9(20.93) 20(46.51) 29(67.44)
TNM stage 0.496 0.007* 0.321 0.03*
Stage I 3(60) 2(40) 2(40) 1(20)
Stage II 14(41.18) 7(20.59) 13(38.24) 22(64.71)
Stage III 12(40) 7(20.59) 17(56.67) 25(83.33)
Stage IV 3(75) 4(100) 3(75) 3(75)
Lymphnodes 0.565 0.551 0.007* 0.050*
Negative 15(40.54) 9(24.32) 12(32.43) 22(59.46)
Positive 17(47.22) 11(30.56) 23(63.89) 29(80.56)
Metastasis 0.196 0.001* 0.265 0.818
Negative 29(42.03) 16(23.19) 32(46.38) 48(69.57)
Positive 3(75) 4(100) 3(75) 3(75)
+High level expression of proteins
*p value ≤0.05. The difference of protein expressions between clinicopathological parameters was statistically significant
Fig. 2 Kaplan-Meier survival analysis in 73 cases of patients with colorectal cancer. The patients with higher stage a, HMGB1 b, CC3 c, Ki67
d, expression were associated with shorter overall survival time
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Table 4 Univariate and multivariate survival analysis of overall survival
Variables Univariate analysis Multivariate analysis
p p RR 95 % CI
Sex (female vs male) 0.5873
Age (≤70 y vs >70y) 0.0962
TNM stage 0.0000* 0.000* 8.19 3.5370-19.0053
Lymph nodes (+ vs -) 0.0000*
Metastasis (+ vs–) 0.0000*
CC3 (high expression vs otherwise) 0.0006* 0.998 1.00 0.3627-2.7655
HMGB1 (high expression vs otherwise) 0.0281* 0.008* 3.55 1.3972-9.0147
RAGE (high expression vs otherwise) 0.3119
Ki67 (high expression vs otherwise) 0.0330* 0.347 1.50 0.6451-3.4806
CI: confidence interval, RR: risk ratio. *statistically significant
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that HMGB1 positively correlated with CC3 and Ki67
level (correlation coefficient 0.5393, 0.3814, respectively;
p <0.001, Table 5). Fig. 3 showed a coordinated expression
of HMGB1, CC3, and Ki67 that they were either all posi-
tive or all negative/low expression in the same visual field.
Discussion
The purpose of tumor therapy is to induce tumor cell
death. However, tumor cell death is not the final step in
overcoming cancer. There is increasing evidence showing
that dying or dead tumor cells can actually promote
tumor development through many mechanisms. There-
fore, it is necessary to investigate the relationship between
death and growth of tumor cells. Our previous studies
have demonstrated that apoptotic tumor cells can stimu-
late the proliferation of residual living tumor cells through
activating caspase-3 and its downstream effectors [2, 3].
However, apoptosis is not the only death modality for irra-
diated tumor cells. Necrosis is also present after irradi-
ation. The mechanism behind dying cells stimulating the
growth of living tumor cells might be rather complex. InTable 5 Relationship between HMGB1 and other protein expression
Total no. (%)
Negative
CC3 Negative 12(16.44) 8
low 29(39.73) 3
high 32(43.84) 1
RAGE Negative 5(6.85) 3
low 17(23.29) 2
high 51(69.86) 7
Ki67 low 38(52.05) 11
high 35(47.95) 1
ρ(rho): Spearman correlation coefficient
*Correlation is statistically significant at 0.05 level (2 tailed)this study, we investigated the role of apoptotic and nec-
rotic cells in tumor progression, and found that, after ir-
radiation, the dying colorectal cancer cells were composed
of both apoptotic and necrotic cells. After irradiation, we
were able to detect secreted HMGB1 before caspase-3
cleavage. Interestingly, a cell proliferation marker, PCNA,
was found to be increased after irradiation, and its expres-
sion paralleled the increased expression of HMGB1 in the
medium after irradiation. In addition, we also examined
clinical colorectal cancer samples and found that HMGB1
is also a marker for poor prognosis. Therefore, this study
may uncover a new mechanism that besides the caspase-3
from apoptotic cells, some other signal molecules, such as
HMGB1 released from the necrotic cells, may also exert a
role in the proliferation of living colorectal cancer cells.
Because active HMGB1 can be released from dead,
dying, and injured cells, it could be a good marker for
necrosis. Obviously, this concept is inaccurate with
regards to current research [7, 8, 27]. This study showed
that the concentrations of HMGB1 in the culture
medium of colorectal cancer cells and cleaved caspase-3
in the colorectal cancer cells were increased afterin 73 cases of colorectal cancer
HMGB1, n ρ(rho) p value
Low High
7 3 0.5393 0.000*
20 12
2 17
0 2 0.0047 0.9683
6 9
23 21
16 11 0.3814 0.0009*
13 21
Fig. 3 HMGB1, CC3, and Ki67 expression in colorectal cancer tissues in serial sectioning slides. (a, b and c) represented the positive
immunohistochemical staining of HMGB1, CC3, and Ki67, respectively, while d, e and f represented the negative staining of the three proteins
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known proliferative marker. This finding supports the idea
that there is a balance between cell death and proliferation
in irradiated cells. Although nuclear HMGB1 acts as a
DNA chaperone, the extracellular HMGB1 is widely
thought of as a signaling molecule and involved in a
variety of physical and pathological processes, such as in-
flammation, cell proliferation and differentiation, and tis-
sue regeneration [6, 8, 27]. It is therefore not difficult to
believe that HMGB1 acts as a proliferation factor that is
involved in the dying-cell-stimulated proliferation of living
tumor cells in this study.
Extracellular HMGB1 acts through binding to several
cell surface receptors, including RAGE [8, 9]. The binding
of HMGB1 to RAGE is thought to stimulate proliferation
and differentiation of cancer cells [10]. Unfortunately, the
dynamic changes in the expression of RAGE in the prolif-
erating living colorectal cancer cells were not evident.
However, in this study, the positive RAGE expression
correlated with higher TNM staging and lymph node me-
tastasis in colorectal cancer patients. The TNM system is
one of the most widely used cancer staging systems that
categorizes the stage of a solid cancer based on the size
and/or extent of the primary tumor (T), the amount of
spread to lymph nodes (N), and the presence of metastasis
(M) [20]. In general, higher TNM staging represents rapid
tumor progression and highly aggressive tumors. The
positive correlation between RAGE expression and TNM
stage suggests that RAGE could possibly be a factor that
influences tumor prognosis. This is also consistent with a
previous report [14].
In addition, this study confirmed the roles of CC3 in
the proliferation of tumor cells as well as its association
with poor prognosis in colorectal cancer patients [3].
The role of proliferative marker Ki67 in colorectalcancer patients was also confirmed and consistent with
PCNA expression in tumor cells studied in vitro as well
as a previous study in CRC patients [22]. This suggests
that the data from the current case series are suitable
for analysis of the clinical significance of HMGB1.
Although HMGB1 showed no association with TNM
staging and metastasis, it did correlate with poor prog-
nosis (p = 0.0281) and is a predictive marker for poor
prognosis according to multivariate analysis. Based on
the histological study and in vitro study, we propose
that both apoptosis and necrosis play an important role
in tumor progression, and both CC3 and HMGB1 are
predictive markers of poor prognosis in colorectal
cancer patients.
Repopulation describes the phenomenon that surviv-
ing tumor cells after radiotherapy reestablish and form a
new tumor [28]. However, the underlying mechanism
has not been fully elucidated. It could be caused by pro-
liferation from lightly injured tumor cells as a result of
heterogeneous reaction to radiation or living tumor cells
that migrated beyond the radiated field. The results from
our study suggested that apoptotic and necrotic cells
could stimulate proliferation of the living tumor cells.
The HMGB1 released from dying cells could be a new
marker to predict the possibility of tumor repopulation.
This may also represent a new mechanism of tumor
repopulation.
In conclusion, repopulation is one of the main obsta-
cles hindering successful cancer treatment. The apop-
totic or necrotic cells can stimulate growth of living
tumor cells and subsequently mediate the relapse of
colorectal cancer after radiotherapy. The increased
expression of the key factors of apoptosis or necrosis
such as CC3 and HMGB1 in tumor could be a new
marker for poor prognosis in colorectal cancer.
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Below is the link to the electronic supplementary material.
Additional file 1: Figure S1. The representative immunohistochemical
staining of different protein expressions (original magnification × 400).
a), b) and c) for negative, low, and high CC3 expression, respectively;
d), e) and f) for negative, low, and high HMGB1 expression, respectively;
g), h) and i) for negative, low, and high RAGE expression, respectively;
j) and k) for low and high Ki67 expression, respectively.
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